GlassScriptPhysician profile
Katelyn Parnell
NPI 1003103771
$2,046.90
in general payments reported to CMS, 2019-2025
35 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $252 · 2021: $322 · 2022: $354 · 2023: $214 · 2024: $332 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.65 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Therapeuticsmd, INC. | $187.09 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $176.26 | 2020-2022 | |
| Pfizer INC. | $130.92 | 2022-2024 | |
| Baxter Healthcare | $124.70 | 2021-2024 | Perclot |
| Coopersurgical, INC. | $115.72 | 2023-2025 | Ally II Ups, Advincula Delineator Uterine Manipulator, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $102.33 | 2019-2025 | |
| Astellas Pharma US INC | $90.15 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $76.17 | 2023-2024 | Myfembree |
| Ethicon US, LLC | $76.07 | 2022-2025 | Stratafix, Vistaseal |
| Organon LLC | $66.99 | 2022-2025 | Jada System |
| Applied Medical Resources Corporation | $60.65 | 2021 | |
| Novo Nordisk INC | $55.90 | 2020-2023 | Wegovy |
| Millicent US INC | $46.24 | 2024-2025 | Femlyv, Intrarosa |
| Hologic Sales and Service, LLC | $43.94 | 2019-2024 | Novasure, Myosure Tissue Removal Device |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $39.38 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $35.90 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.92 | 2022-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $32.49 | 2022-2024 | Gardasil, Gardasil 9 |
| Exeltis, USA INC. | $29.52 | 2019-2023 | Slynd |
| Myovant Sciences INC. | $27.61 | 2021-2022 | |
| Daiichi Sankyo INC. | $23.73 | 2019 | |
| Smith+Nephew, INC. | $18.81 | 2024 | Pico 14 |
| Avion Pharmaceuticals | $15.07 | 2019 | |
| Mayne Pharma Commercial LLC | $13.88 | 2022 | |
| Meditrina | $13.80 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.69 | 2019 | |
| Axsome Therapeutics, INC. | $13.61 | 2025 | Sunosi |
| Endo Pharmaceuticals INC. | $13.22 | 2019 | |
| Boston Scientific Corporation | $13.20 | 2019 | |
| Mission Pharmacal Company | $13.08 | 2020 | |
| Coloplast Corp | $12.63 | 2020 | |
| Lupin INC. | $12.06 | 2020 | |
| Sanara Medtech INC. | $11.89 | 2021 | |
| Evofem Biosciences, INC. | $9.63 | 2025 | Solosec, Phexx, Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Parnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.